Literature DB >> 33991630

Discovery of a novel inhibitor of nitric oxide production with potential therapeutic effect on acute inflammation.

Long-Qing Zhu1, Xiao-Hong Fan1, Jun-Fang Li1, Jin-Hong Chen1, Yan Liang1, Xiao-Ling Hu1, Shu-Meng Ma1, Xiang-Yong Hao2, Tao Shi3, Zhen Wang4.   

Abstract

Inflammation as a host's excessive immune response to stimulation, is involved in the development of numerous diseases. To discover novel anti-inflammatory agents and based on our previous synthetic work on marine natural product Chrysamide B, it and a series of derivatives were synthesized and evaluated for their anti-inflammatory activity on inhibition of LPS-induced NO production. Then the preliminary structure-activity relationships were conducted. Among them, Chrysamide B is the most potent anti-inflammatory agent with low cytotoxicity and strong inhibition on the production of NO (IC50 = 0.010 μM) and the activity of iNOS (IC50 = 0.082 μM) in LPS-stimulated RAW 264.7 cells. Primary studies suggested that the mechanism of action may be that it interfered the formation of active dimeric iNOS but not affected transcription and translation. Furthermore, its good performance of anti-inflammatory effect on LPS-induced multiple inflammatory cytokines production, carrageenan-induced paw edema, and endotoxin-induced septic mice, was observed. We believe that these findings would provide an idea for the further modification and research of these analogs in the future.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Anti-inflammatory activity; Chrysamide B; Nitric oxide; Structure-activity relationship

Mesh:

Substances:

Year:  2021        PMID: 33991630     DOI: 10.1016/j.bmcl.2021.128106

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  1 in total

1.  Inhibition of Lipopolysaccharide-Induced Inflammatory Signaling by Soft Coral-Derived Prostaglandin A2 in RAW264.7 Cells.

Authors:  Osamu Ohno; Eika Mizuno; Junichiro Miyamoto; Tomoyuki Hoshina; Takuya Sano; Kenji Matsuno
Journal:  Mar Drugs       Date:  2022-05-09       Impact factor: 6.085

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.